Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL

NCT ID: NCT01248572

Last Updated: 2014-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this study is to determine the effective lens position (ELP) - or location an intraocular lens (IOL) "sits" in the eye - of the Softec HD IOL. A secondary study goal is to determine if measures of the eye taken prior to surgery can reliably predict postoperative ELP.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to determine the effective lens position (ELP) of the study lens, and to report the stability of ELP post-operatively. Additionally, correlations of ELP to predicted postoperative lens position, capsular bag metrics, preoperative biometry and age will be statistically analyzed for determination of ELP prediction via one, or a combination of preoperative variables.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Softec HD IOL

Group Type EXPERIMENTAL

Softec HD IOL

Intervention Type DEVICE

Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Softec HD IOL

Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>=40 years of age, of any race and either gender
* Operable, age related cataract grade 3+ or lower in the study eye
* Able to achieve best corrected visual acuity (BCVA) 20/30 Snellen or better postoperatively in the study eye
* ≤1.0 diopter (D) of corneal astigmatism preoperatively in the study eye
* Able to achieve a dilated pupil \>6.0 millimeter (mm) in the study eye
* Able to adequately visualize the lens equatorial diameter on ultrasound biomicroscopy (UBM) unit (preoperatively)
* Desire implantation of a monofocal lenses targeted at emmetropia in the study eye
* In good general and ocular health
* Able to competently complete testing
* Willing and able to attend study visits
* Willing and able to understand and sign an informed consent

Exclusion Criteria

* Previous intraocular surgery or laser treatment
* Severe dry eye
* Uncontrolled IOP or glaucoma
* Retinal or macular pathology (i.e. macular degeneration, proliferative diabetic retinopathy, etc.)
* History of retinal detachment
* Microphthalmia
* Chronic severe uveitis
* Corneal decompensation
* Irregular astigmatism
* History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)
* Clinically significant corneal endothelial dystrophy (e.g., Fuchs' dystrophy)
* Pseudoexfoliation syndrome
* Iris atrophy
* Pupil abnormalities (e.g., corectopia)
* Aniseikonia
* Amblyopia
* An acute or chronic disease or illness that may confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness)
* Pregnant, lactating, or planning to become pregnant during the course of the trial
* Participation in another clinical trial within 30 days of study start
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lenstec Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barnet-Dulaney-Perkins Eye Center

Phoenix, Arizona, United States

Site Status

Eye Centers of Florida

Fort Myers, Florida, United States

Site Status

Harbin Clinic

Rome, Georgia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LTHD-10-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.